A detailed history of Harbor Capital Advisors, Inc. transactions in Regenxbio Inc. stock. As of the latest transaction made, Harbor Capital Advisors, Inc. holds 36,082 shares of RGNX stock, worth $274,944. This represents 0.02% of its overall portfolio holdings.

Number of Shares
36,082
Previous 24,298 48.5%
Holding current value
$274,944
Previous $284,000 33.45%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$10.49 - $14.39 $123,614 - $169,571
11,784 Added 48.5%
36,082 $379,000
Q2 2024

Jul 09, 2024

SELL
$11.51 - $21.53 $348,787 - $652,423
-30,303 Reduced 55.5%
24,298 $284,000
Q1 2024

May 13, 2024

BUY
$12.17 - $24.61 $61,482 - $124,329
5,052 Added 10.2%
54,601 $1.15 Million
Q4 2023

Jan 08, 2024

BUY
$12.89 - $20.82 $12,761 - $20,611
990 Added 2.04%
49,549 $889,000
Q3 2023

Oct 20, 2023

BUY
$16.46 - $19.99 $73,296 - $89,015
4,453 Added 10.1%
48,559 $799,000
Q2 2023

Jul 11, 2023

BUY
$17.23 - $21.71 $341,670 - $430,509
19,830 Added 81.69%
44,106 $881,000
Q1 2023

Apr 26, 2023

SELL
$18.08 - $24.55 $43,554 - $59,140
-2,409 Reduced 9.03%
24,276 $459,000
Q4 2022

Jan 20, 2023

SELL
$20.4 - $24.73 $11,709 - $14,195
-574 Reduced 2.11%
26,685 $0
Q3 2022

Oct 28, 2022

SELL
$22.29 - $35.04 $66,691 - $104,839
-2,992 Reduced 9.89%
27,259 $720,000
Q2 2022

Jul 26, 2022

SELL
$19.35 - $35.04 $42,744 - $77,403
-2,209 Reduced 6.81%
30,251 $747,000
Q1 2022

Apr 28, 2022

SELL
$24.62 - $34.31 $142,623 - $198,757
-5,793 Reduced 15.14%
32,460 $1.08 Million
Q4 2021

Feb 04, 2022

BUY
$30.19 - $40.28 $1.15 Million - $1.54 Million
38,253 New
38,253 $1.25 Million

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $329M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Harbor Capital Advisors, Inc. Portfolio

Follow Harbor Capital Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.